Management of Hemodynamically Stable Monomorphic Ventricular Tachycardia Refractory to Amiodarone

Immediate Electrical Cardioversion

• In patients with stable monomorphic VT that does not terminate after a loading dose of amiodarone, synchronized electrical cardioversion should be performed immediately; it remains appropriate at any stage of the treatment cascade. (Class I recommendation) 1
• Cardioversion is the most efficacious acute therapy and should be delivered with appropriate sedation while the patient remains hemodynamically stable. (Class I) 2
• The initial synchronized shock energy should be set to 100 J for monomorphic VT, with stepwise escalation if conversion is not achieved. (Class I) 3

Pharmacologic Second‑Line Therapy

• Intravenous procainamide is the preferred second‑line antiarrhythmic after amiodarone failure, supported by Class IIa, Level B evidence. (Class IIa, Level B) 1
• Procainamide has demonstrated superior acute termination efficacy compared with amiodarone for stable monomorphic VT. (Class IIa) 2
• During procainamide infusion, continuous blood‑pressure and ECG monitoring is mandatory because hypotension is a common adverse effect. (Class I) 2

Ischemic Context Management

• When acute myocardial ischemia is present or suspected, urgent coronary angiography with revascularization should be pursued. (Class I) 1
• Intravenous lidocaine (1 mg/kg bolus, then 0.5 mg/kg every 8–10 min as needed) may be reasonable specifically in the ischemic setting (Class IIb). 2
• Beta‑blockers are especially useful when ischemia is suspected, helping to reduce ventricular ectopy. (Class I) 1

Refractory or Recurrent VT Strategies

• Transvenous catheter pacing can terminate VT that is refractory to cardioversion or recurs despite antiarrhythmic drugs; this is a Class IIa recommendation and requires specialized equipment and expertise. (Class IIa) 2
• For patients with recurrent VT despite prior interventions, a combination of beta‑blockers and procainamide may be considered. (Class IIb) 1
• Emergent catheter ablation should be contemplated for incessant or electrical‑storm VT that cannot be controlled medically. (Class IIa) 1

Contraindicated Therapies

• Calcium‑channel blockers (verapamil or diltiazem) must never be used for wide‑QRS tachycardia of unknown origin, particularly in patients with underlying myocardial dysfunction, as they can precipitate hemodynamic collapse. (Class III) 2

Hemodynamic Assessment Algorithm

• Re‑evaluate hemodynamic status promptly; if the patient shows decompensation (systolic BP < 90 mmHg, pulmonary edema, altered mental status, or chest pain), proceed immediately to synchronized cardioversion regardless of prior pharmacologic attempts. (Class I) 3

Evidence Quality Summary

• The recommendation that procainamide is superior to amiodarone for acute termination of stable monomorphic VT is supported by Class IIa evidence, whereas amiodarone itself carries only a Class IIb recommendation for this indication. (Class IIa vs. Class IIb) 1
• The evidence base is limited by small sample sizes and heterogeneous study designs, but across trials procainamide consistently shows the greatest efficacy for rapid VT conversion. (Level B) 2

Management of Monomorphic Ventricular Tachycardia

Initial Assessment and Management

• The European Society of Cardiology recommends direct-current cardioversion with appropriate sedation at any point in the treatment cascade in patients with suspected sustained monomorphic VT with hemodynamic compromise 4, 5, 6, 7
• Any wide-QRS tachycardia should be presumed to be VT if the diagnosis is unclear, and immediately determine if the patient is hemodynamically stable or unstable 4, 5, 8

Treatment of Hemodynamically Unstable Monomorphic VT

• Immediate direct-current cardioversion with appropriate sedation is recommended for hemodynamically unstable monomorphic VT 4, 5, 6
• If VT recurs after cardioversion, consider intravenous amiodarone (loading dose of 150 mg over 10 minutes, followed by maintenance infusion) 5, 8

Treatment of Hemodynamically Stable Monomorphic VT

• The European Society of Cardiology recommends intravenous procainamide (10 mg/kg at 50-100 mg/min) as a reasonable initial treatment for hemodynamically stable monomorphic VT, with a Class IIa recommendation and Level of Evidence B 4, 5, 7
• Intravenous amiodarone is recommended for VT that is refractory to conversion with countershock or recurrent despite procainamide 4, 5

Special Circumstances

• For VT associated with acute myocardial ischemia/infarction, intravenous lidocaine (1 mg/kg initial bolus, followed by 0.5 mg/kg every 8-10 minutes if needed) is recommended 4, 9
• Urgent coronary angiography with revascularization should be considered for VT associated with acute myocardial ischemia/infarction 5, 8

Important Caveats and Contraindications

• Calcium channel blockers (verapamil, diltiazem) should not be used to terminate wide-QRS-complex tachycardia of unknown origin, especially with history of myocardial dysfunction 4, 5, 8
• Combination therapy with intravenous amiodarone, beta blockers, and intravenous procainamide may be considered for repetitive monomorphic VT in coronary disease or idiopathic VT 4, 6, 7, 10